Answers are grounded in this paper and cite their sources.
ÖZAnaplastic lymphoma kinase (ALK) rearrangement is detected at a low rate in non-small cell lung cancer (NSCLC).Patients with ALK rearrangements have poor responses to conventional cytotoxic chemotherapy.Brigatinib is one of the ALK-tyrosine kinase inhibitors recommended for first-line treatment in metastatic NSCLC.Local ablative therapies are applied in the treatment of oligometastatic disease in NSCLC.In this case, a patient with lung adenocarcinoma with ALK-rearranged isolated adrenal metastasis was treated with adjuvant brigatinib after sequential surgery.A 23-month disease-free survival was obtained.The case reported here represents the use of adjuvant therapy with ALK inhibitors in ALK-positive oligometastatic NSCLC in eligible patients.
No takes yet. Share an insight, caveat, or question.
Ünsal et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: